Rockwell Medical, Inc. Reports Third Quarter 2018 Financial Results

Friday, November 9, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three MonthsEndedSeptember 30, 2018

Three MonthsEndedSeptember 30, 2017

Nine Months EndedSeptember 30, 2018

Nine Months EndedSeptember 30, 2017

Sales

$

16,672,416

$

14,626,904

$

46,534,358

$

42,462,265

Cost of Sales

14,703,606

13,555,853

49,303,048

37,535,454

Gross Profit (Loss)

1,968,810

1,071,051

(2,768,690)

4,926,811

Selling, General and Administrative

6,159,141

4,791,636

15,182,048

17,433,530

Settlement Expense, net of Reimbursement

1,030,000

Research and Product Development

808,192

1,304,658

4,033,494

4,195,003

Operating Loss

(4,998,523)

(5,025,243)

(23,014,232)

(16,701,722)

Interest and Investment Income (Loss)

28,891

(31,751)

264,287

(180,279)

Net Loss

$

(4,969,632)

$

(5,056,994)

$

(22,749,945)

$

(16,882,001)

Basic and Diluted Net Loss per Share

$

(0.10)

$

(0.10)

$

(0.44)

$

(0.33)

Basic and Diluted Weighted Average Shares Outstanding

51,288,537

51,260,975

51,288,462

50,995,079



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store